New Pill-and-Shot combo aims to tame thick blood
NCT ID NCT07445893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new pill (gecacitinib) plus a weekly injection (pegylated interferon) can help people with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to bring blood counts back to normal and ease symptoms. Thirty adults will take the combination for 24 weeks and be closely monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gecacitinib hydrochloride tablets and pegylated interferon alfa-2b
What this could lead to
If successful, this combination could offer a new first-line treatment option to control blood cell counts and reduce symptoms in polycythemia vera patients.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The combination may cause side effects like flu-like symptoms or blood cell changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, China